Evaluation of Health Costs and Resource Utilization

PHASE4TerminatedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Ulcerative ColitisCrohn's Disease
Interventions
OTHER

Measurement of drug (Adalimumab/Infliximab)

Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.

OTHER

Intensify treatment with the existing drug

Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist

Trial Locations (1)

80222

Rocky Mountain Gastroenterology Associates, Denver

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Prometheus Laboratories

INDUSTRY

lead

University of Western Ontario, Canada

OTHER

NCT01960426 - Evaluation of Health Costs and Resource Utilization | Biotech Hunter | Biotech Hunter